Aurinia Pharmaceuticals
AUPH • NASDAQ
Aurinia Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Kevin C. Tang, with a market cap of $1.9B.
CEOKevin C. Tang
Next Earnings
Upcoming earnings announcement for Aurinia Pharmaceuticals
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.20
Revenue Estimate
$77.1M
Earnings History
Past 12 earnings reports for Aurinia Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $0.26Est: $0.21 | +23.8% | $77.1MEst: $74.6M | +3.4% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.23Est: $0.16 | +43.8% | $73.5MEst: $68.0M | +8.0% | 10-Q |
| Jul 31, 2025 | Q2 2025 | $0.16Est: $0.16 | 0.0% | $70.0MEst: $64.3M | +9.0% | 10-Q |
| May 12, 2025 | Q1 2025 | $0.16Est: $0.10 | +60.0% | $62.5MEst: $61.1M | +2.3% | 10-Q |
| Feb 27, 2025 | Q4 2024 | $0.01Est: -$0.02 | +150.0% | $59.9MEst: $59.9M | -0.1% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.10Est: $0.01 | +900.0% | $67.8MEst: $57.7M | +17.5% | 10-Q |
| Aug 1, 2024 | Q2 2024 | $0.01Est: $0.01 | 0.0% | $57.2MEst: $55.1M | +3.9% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.03Est: -$0.14 | +78.6% | $50.3MEst: $47.5M | +6.0% | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$0.19Est: -$0.16 | -18.8% | $45.1MEst: $44.5M | +1.5% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.09Est: -$0.17 | +47.1% | $54.5MEst: $38.5M | +41.6% | — |
| Aug 3, 2023 | Q2 2023 | -$0.08Est: -$0.20 | +60.0% | $41.5MEst: $36.4M | +14.1% | — |
| May 4, 2023 | Q1 2023 | -$0.18Est: -$0.22 | +18.2% | $34.4MEst: $27.9M | +23.5% | — |